Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · October 14, 2024

Risk of Mortality or Rehospitalization After Acute Coronary Syndrome With Glyburide vs Gliclazide Use in Adults With Type 2 Diabetes

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study
Diabetes Obes Metab 2024 Sep 09;[EPub Ahead of Print], W Long, PE Light, SH Simpson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading